Related Experiment Video
Updated: May 3, 2026
A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
Published on: September 20, 2019
MSC-based product characterization for clinical trials: an FDA perspective
Michael Mendicino1, Alexander M Bailey2, Keith Wonnacott3
1Office of the Commissioner (OC), Office of the Chief Scientist (OCS), Office of Regulatory Science and Innovation (ORSI), 10903 New Hampshire Boulevard, Silver Spring, MD 20993, USA; Center for Biologics Evaluation and Research (CBER), Office of Cellular, Tissue and Gene Therapy (OCTGT), Division of Cell and Gene Therapy (DCGT), 1401 Rockville Pike, Rockville, MD 20852, USA.
The number of Mesenchymal Stem Cell (MSC) product proposals is rapidly increasing, showing significant diversity in sources and manufacturing. This variability presents challenges for clinical translation of these advanced therapies.
Area of Science:
- Regenerative Medicine
- Cell-based Therapies
- Biotechnology
Background:
- Mesenchymal Stem Cells (MSCs) are increasingly explored for therapeutic applications.
- Clinical translation of MSC-based products faces regulatory and scientific hurdles.
Purpose of the Study:
- To analyze the diversity of Mesenchymal Stem Cell (MSC)-based product proposals submitted to the FDA.
- To identify potential challenges hindering the clinical translation of MSC therapies.
Main Methods:
- Review of FDA submissions for MSC-based products.
- Analysis of variability in donor/tissue sources, manufacturing, functional mechanisms, and characterization.
Main Results:
- Rapid expansion in MSC product proposals submitted to the FDA.
- Significant heterogeneity observed in donor and tissue sources.
- Variability noted in manufacturing processes, functional mechanisms, and characterization methods.
Conclusions:
- The diversity in MSC product development presents challenges for standardization and regulatory approval.
- Addressing variability is crucial for successful clinical translation of MSC-based therapies.
More Related Videos
05:16Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides
Published on: May 7, 2020
07:40Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
Published on: March 20, 2021
Related Concept Videos
01:11Clinical Trials: Overview
01:16Clinical Trials
There are four phases in a clinical trial. A phase one...
01:29Clinically Relevant Drug Product Specifications: Methods of Establishment
01:28Preclinical Development: Overview
01:22Biopharmaceutical Factors Influencing Drug Product Design: Overview
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...